New PET and MRI Research Suggests that Visceral Fat Reduction May Prevent or Delay Alzheimer’s Disease
Higher visceral adipose tissue reportedly accounted for 77 percent of the association between Alzheimer’s disease and high body mass index (BMI), according to new research presented at the Radiological Society of North America (RSNA) conference.
Visceral fat reduction may have a significant impact in preventing or delaying the onset of Alzheimer’s disease in obese patients, according to emerging findings from positron emission tomography (PET) and magnetic resonance imaging (MRI) research.
For the study, presented at the Radiological Society of North America (RSNA) conference, researchers reviewed brain PET, abdominal MRI and metabolic assessment data for 80 people with an average age of 49.4 and body mass index (BMI) of 32.31. Over 57 percent of the cohort were obese, according to the study.1
The researchers found higher Centiloid scores in obese patients and higher visceral adipose tissue (VAT) accounted for 77 percent of the correlation between high BMI and the development of Alzheimer’s disease. A mediation analysis revealed that VAT plays a prevailing role in mediating the impact of BMI on Centiloid scoring, according to the study authors.1
"Our study showed that higher visceral fat was associated with higher PET levels of the two hallmark pathologic proteins of Alzheimer's disease — amyloid and tau," noted Masha Dolatshahi, M.D., Ph.D., a lead author of the study and a post-doctoral research associate at the Mallinckrodt Institute of Radiology at the Washington University School of Medicine in St. Louis. "To our knowledge, our study is the only one to demonstrate these findings at midlife where our participants are decades out from developing the earliest symptoms of the dementia that results from Alzheimer's disease."
(Editor’s note: For additional coverage from the 2024 RSNA conference, click here.)
The study authors also noted significant correlations to higher Centiloid scores with increased subcutaneous adipose tissue, BMI, and Homeostatic Model Assessment for Insulin Resistance (HOMAIR) evaluations.
"A key implication of our work is that managing Alzheimer's risk in obesity will need to involve targeting the related metabolic and lipid issues that often arise with higher body fat," explained Cyrus A. Raji, M.D., Ph.D., a senior author of the study and an associate professor of radiology at the Mallinckrodt Institute of Radiology.
Reference
1. Dolatshahi M, Commean P, Naghashzadeh M, et al. The association between body fat localization, insulin resistance, and amyloid burden in midlife. Poster presented at the Radiological Society of North America (RSNA) 2024 110th Scientific Assembly and Annual Meeting Dec. 1-5, 2024. Available at: https://www.rsna.org/annual-meeting .
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
